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Abstract
Background: Intravenous iron is typically administered during the hemodialysis (HD) procedure.
HD patients may be prescribed high-flux (HF) or high-efficiency (HE) dialysis membranes. The
extent of iron sucrose and iron dextran removal by HD using HF or HE membranes and by
ultrafiltration rate (UFR) is unknown.
Methods: Two in vitro HD systems were designed and constructed to determine the dialyzabiltiy
of iron from a simulated blood system (SBS) containing 100 mg iron sucrose or iron dextran
(system A) or 1000 mg iron sucrose (system B). Both in vitro systems utilized a 6-L closed-loop SBS
system that was subject to 4 different HD conditions conducted over 4 hours: HE membrane + 0
ml/hr UFR; HE membrane + 500 ml/hr UFR; HF membrane + 0 ml/hr UFR; HF membrane + 500
ml/hr UFR. Blood flow and dialysate flow rates were 500 ml/min and 800 ml/min, respectively. The
dialysate compartment was a 192-L open system for system A and a 6-L closed-loop system for
system B. Samples from the SBS and dialysate compartments were taken at various time points and
iron elimination rate and HD clearance was determined. Iron removal from the SBS > 15% was
considered clinically significant.
Results: The greatest percentage removal from the SBS was 13.5% and -0.03% utilizing system A
and B, respectively. Iron sucrose and iron dextran dialysate concentration was below the lower
limits of assay (< 2 ppm) for system A. Dialysate recovery of iron was negligible: 0 – 5.4 mg system
A and 5.47 – 23.59 mg for system B. Dialyzer type or UFR did not affect iron removal.
Conclusion: HF or HE dialysis membranes do not remove clinically significant amounts of iron
sucrose or dextran formulations over a 4-hour HD session. This effect remained constant even
controlling for UFR up to 500 ml/hour. Therefore, iron sucrose and iron dextran are not dialyzed
by HE or HF dialysis membranes irrespective of UFR.
Background
Iron deficiency is a common problem in hemodialysis
(HD) patients [1]. Reasons for iron deficiency include
increased requirements due to erythropoetin-stimulated
red blood cell production, blood loss through the HD
procedure, and impaired absorption of oral iron [2]. As
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such, many patients require supplementation with intra-
venous (IV) iron to maintain transferrin saturations >
20% and ferritin concentrations > 100 ng/mL [1].
Iron dextran (InFed®, Watson Pharmaceuticals; DexFer-
rum®, American Regent, Inc.) was the first IV iron prepara-
tion used in HD patients. However, concerns over iron
dextran side effects, specifically anaphylactic and anaphy-
lactoid reactions [3], lead to development of other safer IV
iron preparations. One such IV iron preparation available
for use in HD patients is iron sucrose (Venofer®, American
Regent Laboratories, Inc.).
It is recommended that iron sucrose be given by slow
injection or infusion during the HD session to patients
that require supplemental IV iron [4]. Previous reports
have shown that very little iron dextran (InFed®, Watson
Pharmaceuticals, molecular weight 90,000 daltons [5]) is
removed via HD [6-8]. However it is unknown to what
extent the HD procedure removes the other iron dextran
product (DexFerrum®, American Regent, Inc., molecular
weight 265,000 daltons [5]) or iron sucrose (Venofer®,
American Regent, Inc., molecular weight 34,000 – 60,000
daltons [4]).
Iron sucrose, also known as iron saccharate, is a complex
of polynuclear iron (III)-hydroxide in sucrose for intrave-
nous use. Iron sucrose has a molecular weight of approxi-
mately 34,000 – 60,000 Daltons and a proposed
structural formula:
[Na2Fe5O8(OH)*3(H2O)]n*m(C12H22O11). The
molecular weight of iron sucrose ranges 34,000 – 60,000
daltons as during the manufacturing process, the number
of sucrose molecules bound to iron varies [4].
Given the differences between iron dextran products and
iron sucrose regarding molecular weight and pharmacok-
inetic profile [9], one cannot assume that the HD clear-
ances will be the same.
HD patients may be prescribed high-flux (HF) or high-
efficiency (HE) dialysis membranes. HF and HE dialysis
membranes have very different solute clearance capabili-
ties. These membranes can remove molecular weight sub-
stances up to approximately 15,000 daltons[10]. Iron
removal by HD may also be dependant upon convection
(i.e., solute drag), which is controlled by the ultrafiltration
rate (UFR) The extent of iron removal in HD patients
using HF or HE membranes or varying UFR needs to be
investigated.
Therefore, an in vitro HD study was conducted to deter-
mine whether HF or HE dialysis membranes, under vari-
ous UFR, removed clinically important amounts of iron
dextran or iron sucrose from a simulated blood system.
The null hypothesis was that newer HF or HE dialysis
membranes removed iron in clinically significant
amounts and that the removal was dependent of UFR.
Methods
In-vitro hemodialysis system A
A closed-loop fixed volume reservoir of 6-L normal saline
solution (5750 ml reservoir + 250 ml tubing and dialysis
membrane volume) was prepared for a simulated blood
system (SBS). A 1000 ml graduated cylinder was used to
measure out the normal saline. The normal saline had a
pH = 5.0 and an osmolarity of 308 mOsmol/l. The SBS
was maintained at 37°C and continuously mixed
throughout the in vitro HD session. The blood flow rate
(BFR) and dialysate flow rate (DFR) was maintained at
500 ml/min and 800 ml/min, respectively. To assess the
contribution of convection to drug removal, UFR was set
at 0 ml/hr for one-half of the HD sessions and at 500 ml/
hr for the other half of the HD sessions. A volumetric HD
machine (model 2008H, Fresenius USA, Walnut Creek,
CA) controlled all BFR, DFR, and UFR. Two dialysis mem-
branes were tested: CA210 (Baxter) a HE dialyzer and
F80A (Fresenius) a HF dialyzer. HD was conducted for 4
hours with UFR a 0 ml/hr and for 4 hours at 500 ml/hr.
The dialysate solution ran counter current to SBS within
the dialysis membrane. The dialysate temperature was
maintained at 37°C. Each HD procedure was conducted
in duplicate.
In-vitro hemodialysis system B
Similar to system A, a closed-loop fixed volume reservoir
of 6-L normal saline solution (5750 ml reservoir + 250 ml
tubing and dialysis membrane volume) was prepared for
a SBS. A 1000 ml graduated cylinder was used to measure
out the normal saline. The normal saline had a pH = 5.0
and an osmolarity of 308 mOsmol/l. The SBS was main-
tained at 37°C and continuously mixed throughout the in
vitro HD session.
The dialysate compartment was also a closed-loop 6-L
compartment. A 1000 mL graduated cylinder was used to
measure out the dialysate. The dialysate compartment
consisted of a holding tank and a pressure chamber. A
Shur-Flo® pump (model 4UN54) was used to pump dia-
lysate from the holding tank to the pressure chamber. The
pressure chamber was pressurized to at least 20 psi to pro-
vide sufficient fluid pressure for the dialysis machine. This
dialysate pressure was necessary for the dialysis machine
to operate and control the dialysate flow rate at 800 ml/
min. Spent dialysate from the hemodialysis machine was
collected in the dialysate holding tank. The holding tank
dialysate compartment construction allowed for sampling
to occur through the top of the holding tank.BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/1
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The SBS and dialysate compartment was maintained at
37°C and continuously mixed throughout the in vitro HD
session. The BFR and DFR was maintained at 500 ml/min
and 800 ml/min, respectively.
Sample preparation and collection
For the in vitro system A study, iron sucrose 100 mg (5 ml
of 20 mg/ml solution) or iron dextran 100 mg (2 ml of 50
mg/ml solution) was injected into the SBS. Samples (5
ml) were collected from SBS at 0, 15, 30, 60, 120,180, and
240 min. Collected samples were stored at 25°C until
analysis.
Dialysate was sampled (5 ml) at 0, 60, 120, 180, and 240
min. All dialysate during the simulated HD session was
collected pooled, volume measured, and then sampled (5
ml) for iron sucrose or iron dextran concentration. The
dialysate sample was stored at 25°C until analysis.
For the in vitro system B study, iron sucrose 1000 mg (50
cc of 20 mg/ml solution) was injected into the SBS. Sam-
ples (15 ml) were collected from SBS and dialysate com-
partment at 0, 15, 30, 60, 120,180, and 240 min.
Collected samples were stored at 25°C until analysis. All
dialysate during the simulated HD session was collected
pooled, volume measured, and then sampled (15 ml) for
iron sucrose. The dialysate samples were stored at 25°C
until analysis.
The iron sucrose sample preparation and data analysis
occurred at a Dialysis Clinic, Inc dialysis unit in Kansas
City, MO. The iron dextran sample preparation and data
analysis occurred at a Renal Research Institute dialysis
unit in Albany, NY. Both centers utilized bicarbonate
based dialysate solutions.
Control for potential iron contamination
Disposable supplies (e.g., plastics) were utilized whenever
possible and the use of glassware was not permitted to
minimize iron loss. Additionally, to control for potential
iron contamination within the HD procedure, an addi-
tional HD session was conducted without iron sucrose or
iron dextran injected into the reservoir [SBS]. Dialysate
and SBS samples were then collected at same time points
as described previously. Any detectable iron found in the
SBS or dialysate compartments (native iron) was then
subtracted from measured iron concentration from the
iron-containing HD sessions.
Samples analysis
The determination of iron concentration in study samples
was performed using atomic absorption spectrophotome-
try. A Perkin-Elmer AAnalyst 300 was set up and operated
as per previously described methods.[11] The instrument
is equipped with a Perkin-Elmer Lumina™ Fe hollow cath-
ode lamp, with an emission line of 248.3 nm and an air
acetylene flame. A stock standard solution of ferrous
ammonium sulfate in calcium chloride was used to run a
5-point standard calibration curve, ranging from 2.0 to
10.0 ppm of iron. This method has been validated for rug-
gedness, method and system precision, giving an overall
testing variation of approximately 2%.
In vitro system A
Prior to analysis samples were prepared by pipetting 2.0
mL of sample into a 10.0 mL volumetric flask using a "to
contain" pipette. Pipettes were then rinsed with a calcium
chloride solution and 0.5 mL of HCl was added to the vol-
umetric flask. Sufficient amount of calcium chloride solu-
tion as then added to yield theoretical concentration of
3.33 µg/mL (100 mg/6000 mL × 2.0 mL/10.0 mL × 1000
µg/mg).
In vitro system B
Prior to analysis samples from the SBS compartment were
prepared by pipetting 2.0 mL of sample into a 50 mL vol-
umetric flask using a "to contain" pipette. Pipettes were
then rinsed with a calcium chloride solution and 2.0 mL
of HCl added to the volumetric flask. Sufficient amount of
calcium chloride solution (q.s. to 50 mL) was added to
yield theoretical concentration of 6.664 µg/mL (1000 mg/
6000 mL × 2.0 mL/50 mL × 1000 µg/mL).
Analysis of samples from the dialysate compartment was
prepared by pipetting 3.0 mL of sample into a 10 mL vol-
umetric flask using a "to deliver" pipette and adding 0.5
mL of HCl to the volumetric flask. Sufficient amount of
calcium chloride solution (q.s. to 10 mL) was added to
yield theoretical detection limit of no less than 1.666 µg/
mL (i.e. 1% iron transfer)
SBS initial iron concentration (1000 mg/6000 mL = 166.6
µg/mL).
166.6 µg/mL × 1% / 100 = 1.666 µg/mL
1.666 µg/mL × 3 mL/10 mL = 0.5 µg/mL
In the event that a dialysate sample's determined concen-
tration falls outside of the system's calibration curve of 10
ppm (i.e., greater than 20% iron transfer), the sample's
preparation was adjusted so that the final determined
concentration would fall within the system's calibration
range of 0 to 10 ppm elemental iron.
All sample analysis occurred at a central laboratory
(American Regent, Inc. Shirley, NY). Each system was vis-
ually inspected for color change in either SBS or dialysate
compartment.BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/1
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Data analysis
The mean ± SD iron concentrations were calculated for
each sample taken at each time point for iron sucrose or
iron dextran. The percent change in iron concentration
from beginning to end of HD session and absolute
amount of iron eliminated was calculated. A mean loss of
greater than 15% from the SBS of the initial concentration
was considered as a clinically important loss of iron.
Iron sucrose and iron dextran concentration results were
modeled using PK-Analyst® (MicroMath, version 1.0, Salt
Lake City, UT) pharmacokinetic data analysis software. A
monoexponential model was assumed and pharmacoki-
netic parameters were calculated using the following
formulae:
1. Elimination rate constant for HD period (Khd) was
calculated:
A positive rate constant Khd suggests accumulation of sub-
stance in the tank; whereas a negative rate constant Khd
suggests removal of substance from the tank.
2. The amount removed (A) by HD was calculated as the
mean of:
A = (preHD conc - end of HD conc) * Volume of distribu-
tion (Vd) and
A = total iron sucrose or iron dextran collected in dialysate
Vd = SBS volume + tubing volume + dialyzer volume
3. Clearance HD (Clhd) = Slope of regression line × Vd.
Clearance values that are positive relate to accumulation
of substance from the system; negative clearance values
represent removal of substance from the system.
Statistics
Iron product pharmacokinetic parameters determined
from samples obtained during HF and HE dialysis mem-
branes were compared using two-sample t-test. Pharma-
cokinetic parameter values at 0 ml/hr and 500 ml/hr UFR
were compared using a paired t-test. Finally pharmacoki-
netic parameters between iron sucrose and iron dextran
compounds were compared using two-sample t-test. All t-
tests were two-tailed and a p-value < 0.05 was considered
significant.
Results
In vitro system A
Instillation of iron sucrose or iron dextran into the SBS
resulted in a light brown colored solution. The dialysate
compartment consisted of a clear solution. During the
entire study there was no visual evidence of color change
in the SBS or dialysate compartments.
The mean ± SD dialysate iron recovery values for iron
sucrose from each HD session utilizing HF or HE dialyzers
and 0 ml/min and 500 ml/min UFR test condition is
reported in Table 1. At no time was any iron detected in
the dialysate in the iron sucrose experiments, regardless of
the dialysis membrane used. The amounts of iron meas-
ured in the dialysate compartment were below the limits
of detection for the assay (< 2 ppm). The mean ± SD dia-
lysate iron recovery for iron dextran from each HD session
utilizing HF or HE dialyzers and 0 ml/min and 500 ml/
min UFR test condition is reported in Table 2. In contrast
to iron sucrose, some iron (5.44 ± 7.7 mg) from the iron
dextran was found in the dialysate when using HE mem-
branes at 0 UFR. However, under other dialysis conditions
with HE or HF membranes, no iron was found.
K
preHD concentration / end of HD concentration
time
hd
h
= () ln
d d
Table 1: Iron sucrose removal by high-flux or high-efficiency hemodialysis membranes over 240 minutes. (System A)
Iron Sucrose (Venofer®)
Study condition SBS % iron 
concentration change
(mean ± SD)
Khd (hr-1)
(mean ± SD)
Dialysate Iron Recovery 
(mg)
(mean ± SD)
Clearance† (ml/min)
(mean ± SD)
F80: 0 ml/hr UFR 13.55 ± 1.56 0.0006 ± 0.0001 0.00 ± 0.00 3.62 ± 0.45
F80: 0 ml/hr UFR Re-run* 6.99 ± 8.55 0.0003 ± 0.0004 0.00 ± 0.00 1.85 ± 2.29
F80: 500 ml/hr UFR -16.03 ± 8.57 -0.0006 ± 0.0003 0.00 ± 0.00 -2.46 ± 1.23
CA210: 0 ml/hr UFR -6.20 ± 1.78 -0.0003 ± 0.0001 0.00 ± 0.00 -1.49 ± 0.42
CA210: 500 ml/hr UFR -14.79 ± 31.51 -0.0003 ± 0.0019 0.00 ± 0.00 -6.87 ± 7.74
SBS = simulated blood solution; UFR = ultrafiltration rate; Khd = hemodialysis elimination rate; % = percent; * = The re-run study condition was an 
unique experiment that replicated all conditions present in the original F80: 0 ml/hr UFR experiment. † = Clearance values that are positive relate 
to accumulation of substance from the system; negative clearance values represent removal of substance from the system.BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/1
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In general, no iron or insignificant levels in the case of
iron dextran was lost from the SBS reservoir for either iron
product. However in the experiment in which iron sucrose
and HF membranes were run at 0 UFR, significant amount
of iron (13.55% ± 1.56) were lost from the SBS reservoir
at 240 minutes (Table 1.). This finding contributed to
greater elimination rate (p = 0.003), clearance (p = 0.003),
and greater amount of iron removed (p = 0.005) between
the HF and the HE dialysis membranes. Since these results
were very disparate to other HD conditions tested and
since no other iron was recovered from the dialysate
under these conditions, the entire experiment was re-run
under the identical condition (HF membrane; 0 UFR; 500
mL/min BFR; 800 mL/min DFR; 4 hours). Results from
the re-run test condition are provided in table 1. During
the re-run experiment, some iron (6.99% ± 8.55) was
again lost from the SBS reservoir, but again no compara-
ble increase in iron was found in the dialysate. Statistical
analysis of the data including data from the re-run yielded
non-significant comparisons between elimination rate (p
= 0.24), clearance (p = 0.24), and greater amount of iron
removed (p = 0.22) between the HF and the HE dialysis
membranes. In conclusion, no significant amount of iron
was found in the dialysate regardless of dialysis mem-
brane used or UFR. Furthermore, no significant loss of
iron was observed in the SBS reservoir irrespective of iron
product used or the test conditions.
In vitro system B
Instillation of 1000 mg iron sucrose into the SBS resulted
in a dark brown (nearly black) colored solution. The
dialysate compartment consisted of a clear solution. Dur-
ing the entire study there was no visual evidence of color
change in the SBS compartment. The dialysate compart-
ment became lightly yellowish in color by the end of 240
minutes.
The mean ± SD percentage recovery from each HD session
utilizing HF or HE dialyzers and 0 ml/min and 500 ml/
min UFR test condition are reported in Table 3. Iron
sucrose SBS percent removal ranged from – 3.13 ± 0.06%
to -0.30 ± 1.15%. Iron sucrose elimination rate from the
SBS was less than 0.0001 hr-1 for all conditions. The dia-
lysate recovery of iron sucrose ranged from 2.79 ± 1.89 mg
to 23.59 ± 3.96 mg when 1000 mg was instilled in the SBS
reservoir (i.e., 0.3 – 2.4% injected iron from SBS compart-
ment). Within dialyzer type and between dialyzer types
statistical analysis revealed non-significant comparisons
between elimination rate, clearance, and percent removed
by dialysis. These non-significant results remained while
controlling for UFR.
Discussion
Intravenous iron is frequently given to HD patients to
treat or prevent iron deficiency anemia[1]. Clinicians may
have concern over the dialyzability of iron sucrose or iron
dextran administered at anytime point during the HD ses-
sion. This is the first study to investigate the in-vitro dialyz-
ability of iron sucrose (Venofer, American Regent, Inc.) or
iron dextran (DexFerrum, American Regent, Inc.).
The appearance of iron sucrose or iron dextran in the dia-
lysate compartment is the best determinate of the
respected agent's dialyzability. The results of our study
demonstrate that no iron sucrose was ever detected in the
dialysate and a negligible amount of iron from the iron
dextran (maximum 5.44% of administered dose) was
recovered from the dialysate compartment only with the
HE membranes at 0 ml/hr UFR. In all other conditions, no
iron was detected in the dialysate for iron dextran. These
effects remained constant even controlling for UFR up to
500 ml/hr. The HF and HE dialysis membranes do not
remove clinically significant amounts of these iron formu-
lations from the SBS compartment over a 240-minute HD
session.
Our results are consistent to previous in-vitro and in-vivo
reports [6-8]. In a 30-minute HD in-vitro  study iron
Table 2: Iron dextran removal by high-flux or high-efficiency hemodialysis membranes over 240 minutes. (System A)
Iron Dextran (DexFerrum®)
Study condition SBS % iron 
concentration change
(mean ± SD)
Khd (hr-1)
(mean ± SD)
Dialysate Iron Recovery 
(mg)
(mean ± SD)
Clearance† (ml/min)
(mean ± SD)
F80: 0 ml/hr UFR -9.69 ± 3.31 -0.0004 ± 0.0001 0.00 ± 0.00 -2.29 ± 0.75
F80: 500 ml/hr UFR -7.84 ± 0.73 -0.0003 ± 0.0000 0.00 ± 0.00 -1.26 ± 0.11
CA210: 0 ml/hr UFR -8.77 ± 6.76 -0.0003 ± 0.0003 5.44 ± 7.70 -2.06 ± 1.54
CA210: 500 ml/hr UFR -7.48 ± 3.54 -0.0003 ± 0.0001 0.00 ± 0.00 -1.20 ± 0.55
SBS = simulated blood solution; UFR = ultrafiltration rate; Khd = hemodialysis elimination rate; % = percent; † = Clearance values that are positive 
relate to accumulation of substance from the system; negative clearance values represent removal of substanceBMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/1
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dextran removal was determined for HF and HE dialyzers
[7]. The greatest amount of iron removed (8%) was
observed with a F8 (Fresenius) HF dialyzer [7]. Other
investigators utilizing a cuprophane coil dialyzer in-vitro
system determined a 0.5% iron dextran removal over 240
minutes [6]. The only in-vivo dialyzability study utilized
iron dextran and HE membranes (Terumo 165 cupram-
monium dialyzer) [8]. The investigators determined a
maximal 2% iron dextran removal over 160 minutes.
At no time point over the sample collection period addi-
tional iron was injected into the SBS or dialysate compart-
ments. However, negative regression analyses (Khd) and
clearance results reported in the tables suggest that there
are increasing amounts of iron in the system (i.e., appear-
ance of additional iron). These findings may be the result
of error amplification through multiplication of meas-
ured iron concentration and volume of dialysate or SBS
reservoir at various time points. Sources of potential error
include human (sample preparation), device (1000 mL
graduated cylinder) and the atomic absorption spectro-
photometry assay. Nonetheless, these negative value
results suggest that no iron sucrose or iron dextran was
removed from the SBS.
The positive iron sucrose regression analyses (Khd) and
clearance results (Table 1) obtained from the HF mem-
brane 0 UFR HD session, support the decreasing amounts
of iron in the SBS system (6.99%). However, no iron
sucrose was found in the dialysate compartment. A poten-
tial reason for the drop in iron sucrose in the SBS compart-
ment is iron sucrose adsorption to the dialysis membrane
or tubing. This effect was not seen with the HE membrane
nor was it observed under dialysis conditions with a pos-
itive UFR.
In order to determine whether the decreasing amounts of
iron were due to either adsorption to the dialysis mem-
brane or actual loss of iron to the dialysate compartment,
the closed-loop studies were conducted (in vitro system B).
In those studies between 0.3 and 2.4% (23.59 mg of 1000
mg dose) of iron sucrose was recovered in the dialysate
compartment when using 1000 mg of iron sucrose (10
times the current recommended dose) in the SBS reser-
voir. Therefore, the majority of loss seen in the earlier
experiments with HF membranes is not due to transfer of
iron to the dialysate compartment; rather the loss is prob-
ably due to adsorption to the dialysis membranes.
A potential limitation to our in-vitro model is that we uti-
lized normal saline instead of blood in our SBS. Use of an
in-vitro model raises concerns over the ability to extrapo-
late the data to humans. In regards to the various intrave-
nous iron formulations, iron appears to dissociate from
sucrose rapidly allowing for more immediate systemic
iron utilization. This is illustrated in a study which com-
pared iron sucrose, iron dextran and iron gluconate [12].
In that study, serum iron, ferritin and transferrin satura-
tion increased more rapidly and were significantly higher
in those patients who received iron sucrose compared to
the other iron products. The pharmacokinetic profile of
iron sucrose in normal healthy adults suggests that the
dissociation of iron from the iron sucrose complex allow
for immediate and substantial iron availability. However,
it is unknown whether HD would remove the iron more
rapidly than it is utilized. Even if the iron in our in-vitro
study was 100% dissociated from the iron sucrose com-
plex, we recovered virtually no iron in the dialysate and
the percent change in iron concentration from baseline
was minimally lower with HE dialyzers under 0 ml/hr
UFR. No loss of iron was detected under other test condi-
tions with HE or HF membranes. Therefore, HD would
not remove significant amounts or iron sucrose prior to it
being utilized in the body.
Table 3: Iron sucrose removal in a closed-loop system by high-flux or high-efficiency hemodialysis membranes over 240 minutes. 
(System B)
Iron Sucrose (Venofer®)
Study condition SBS % iron 
concentration change
(mean ± SD)
Khd (hr-1)
(mean ± SD)
Dialysate Iron Recovery 
(mg)
(mean ± SD)
Clearance† (ml/min)
(mean ± SD)
F80: 0 ml/hr UFR -3.13 ± 0.06 -0.0001 ± 0.0000 13.82 ± 13.34 -0.76 ± 0.01
F80: 500 ml/hr UFR -0.03 ± 1.15 0.0000 ± 0.0000 23.59 ± 3.96 0.05 ± 0.19
CA210: 0 ml/hr UFR -1.41 ± 3.77 -0.0001 ± 0.0002 5.47 ± 1.52 -0.34 ± 0.92
CA210: 500 ml/hr UFR -1.58 ± 3.08 -0.0003 ± 0.0002 2.79 ± 1.89 -1.08 ± 0.93
SBS = simulated blood solution; UFR = ultrafiltration rate; Khd = hemodialysis elimination rate; % = percent; † = Clearance values that are positive 
relate to accumulation of substance from the system; negative clearance values represent removal of substancePublish with BioMed Central    and   every 
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Conclusion
It is therefore concluded that iron sucrose (Venofer®,
American Regent, Inc.) and iron dextran (DexFerrum®,
American Regent, Inc.) are not significantly removed by
either HF or HE dialysis membranes. Furthermore, under
laboratory conditions in a closed-loop system, a maxi-
mum of 2.4% of iron sucrose is found in the dialysate,
well below the clinically relevant level of 15%. These data
show that neither iron dextran or iron sucrose are signifi-
cantly dialyzed under conditions that mimic the clinical
situation.
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